Comparison of LMA® Gastro™ airway and gastrolaryngeal tube in endoscopic retrograde cholangiopancreatography: a prospective randomized observational trial

Uysal, Harun; Şentürk, Hakan; Çalım, Muhittin; Daşkaya, Hayrettin; Guney, Ihsan; Karaaslan, Kazım

doi:10.23736/s0375-9393.21.15371-4

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LMA Gastro is a new second-generation supraglottic airway device with a separate gastric port that has been developed for use during upper gastrointestinal endoscopic procedures [29]. Several retrospective observational studies [30,31] and prospective studies [32,33 ▪▪ ] have reported that the LMA Gastro is easily placed and well tolerated to use in upper gastrointestinal endoscopy and ERCP. In the only randomized trial to date (published in 2021), Uysal et al compared the LMA Gastro with the Gastric Laryngeal Tube [33 ▪▪ ].…”

Section: Devicesmentioning

confidence: 99%

“…Several retrospective observational studies [30,31] and prospective studies [32,33 ▪▪ ] have reported that the LMA Gastro is easily placed and well tolerated to use in upper gastrointestinal endoscopy and ERCP. In the only randomized trial to date (published in 2021), Uysal et al compared the LMA Gastro with the Gastric Laryngeal Tube [33 ▪▪ ]. Successful insertion at first attempt was 72% in Gastric Laryngeal Tube group and 96% in LMA Gastro group.…”

Section: Devicesmentioning

confidence: 99%

See 1 more Smart Citation

Sedation/analgesia techniques for nonoperating room anesthesia: new drugs and devices

Finlay

Leslie

2021

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this article is to review new drugs and devices for nonoperating room anesthesia (NORA). Recent findingsRemimazolam is an ultra-short-acting, water-soluble intravenous benzodiazepine with a fast onset and offset that has been approved recently for use in procedural sedation. Phase III trials have established the effectiveness of remimazolam sedation compared with placebo and midazolam in gastrointestinal endoscopy and bronchoscopy. More research is required investigating remimazolam in real-world NORA settings, including comparisons with propofol sedation. Oliceridine is a m-agonist with selectivity for the G protein pathway and low potency for b-arrestin recruitment. As such it may be associated with less nausea, vomiting and respiratory depression than traditional opioids used. Although no studies have been published about oliceridine use in NORA to date, results from surgical studies indicate a potential place in nonoperating room practice. Research continues into alternative methods of drug delivery, such as patientcontrolled sedation but no new devices are described. SummaryFurther studies are required before these new drugs and devices are embraced in NORA.

show abstract